{
    "clinical_study": {
        "@rank": "57131", 
        "arm_group": {
            "arm_group_label": "Regorafenib", 
            "arm_group_type": "Experimental", 
            "description": "This is an open-label, phase II study of regorafenib for patients with metastatic colorectal carcinoma. The treatment will be repeated every week for three weeks on and one week off. Patients will be evaluated for response after every 2 cycles (8 weeks)."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the good and bad effects when regorafenib is used\n      instead of standard combination chemotherapy. It is not known if taking regorafenib versus\n      standard chemotherapy will have better, worse or the same results."
        }, 
        "brief_title": "Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma", 
        "condition": "Metastatic Colorectal Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years.\n\n          -  Life expectancy of at least 12 weeks (3 months).\n\n          -  Untreated for colorectal cancer, except with adjuvant FOLFOX > 4 weeks prior to\n             recurrence\n\n          -  Histologically proven colorectal adenocarcinoma\n\n               -  Metastatic disease, unresectable disease involving one or more sites including\n                  liver, lung, lymph nodes and peritoneum, with each lesion measuring \u22643cm.\n\n          -  ECOG 0 or 1\n\n          -  Adequate bone marrow, liver and liver function as assessed by the following\n             laboratory requirements:\n\n          -  Total bilirubin \u2264 1.5 x the upper limits of normal (ULN)\n\n          -  Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) \u2264 2.5 xULN (\u2264 5\n             x ULN for subjects with liver involvement of their cancer)\n\n          -  Alkaline phosphastase limit \u2264 2.5 x ULN (\u2264 5 x ULN for subjects with liver\n             involvement of their cancer)\n\n          -  Lipase \u2264 1.5 x the ULN\n\n          -  Serum creatinine \u2264 1.5 x the ULN\n\n          -  Platelet count \u2265 100000 /mm3\n\n          -  hemoglobin (Hb) \u2265 9 g/dL,\n\n          -  absolute neutrophil count (ANC) \u2265 1500/mm3.\n\n          -  Blood transfusion to meet the inclusion criteria will not be allowed.\n\n          -  Glomerular filtration rate (GFR) \u2265 30 ml/min/1.73 m2 according to the Modified Diet\n             in Renal Disease (MDRD) abbreviated formula.\n\n          -  Women of childbearing potential must have a negative serum pregnancy test performed\n             within 7 days prior to the start of study drug. Post-menopausal women (defined as no\n             menses for at least 1 year) and surgically sterilized women are not required to\n             undergo a pregnancy test.\n\n          -  Subjects (men and women) of childbearing potential must agree to use adequate\n             contraception beginning at the signing of the ICF until at least 3 months after the\n             last dose of study drug. The definition of adequate contraception will be based on\n             the judgment of the principal investigator or a designated associate.\n\n          -  Subject must be able to swallow and retain oral medication.\n\n          -  If the patient is one of the first 12 patients enrolled he/she must consent to a pre\n             and post treatment biopsy (or have archived tissue available for the pretreatment\n             analysis).\n\n        Exclusion Criteria:\n\n          -  Uncontrolled hypertension (systolic pressure >140 mm Hg or diastolic pressure > 90 mm\n             Hg [NCI-CTCAE v4.0] on repeated measurement) despite optimal medical management.\n\n          -  Active or clinically significant cardiac disease including:\n\n          -  Congestive heart failure - New York Heart Association (NYHA) > Class II.\n\n          -  Active coronary artery disease.\n\n          -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or\n             digoxin.\n\n          -  Unstable angina (anginal symptoms at rest), new-onset angina within 3 months before\n             randomization, or myocardial infarction within 6 months before randomization.\n\n          -  Evidence or history of bleeding diathesis or coagulopathy.\n\n          -  Any hemorrhage or bleeding event \u2265 NCI CTCAE Grade 3 within 4 weeks prior to start of\n             study medication.\n\n          -  Subjects with any previously untreated or concurrent cancer that is distinct in\n             primary site or\n\n          -  histology from colorectal cancer except cervical cancer in situ, treated basal cell\n             carcinoma, or superficial bladder tumor. Subjects surviving a cancer that was\n             curatively treated and without evidence of disease for more than 3 years before\n             enrollment are allowed.\n\n          -  Known history of human immunodeficiency virus (HIV) infection or current chronic or\n             active hepatitis B or C infection requiring treatment with antiviral therapy.\n\n          -  Ongoing infection > Grade 2 NCI-CTCAE v4.0.\n\n          -  Symptomatic metastatic brain or meningeal tumors.\n\n          -  Presence of a non-healing wound, non-healing ulcer, or bone fracture.\n\n          -  Patients with seizure disorder requiring medication.\n\n          -  Persistent proteinuria \u2265 Grade 3 NCI-CTCAE v4.0 (> 3.5 g/24 hrs, measured by urine\n             protein:creatinine ratio on a random urine sample).\n\n          -  Interstitial lung disease with ongoing signs and symptoms at the time of informed\n             consent.\n\n          -  Pleural effusion or ascites that causes respiratory compromise (\u2265 NCI-CTCAE version\n             4.0 Grade 2 dyspnea).\n\n          -  History of organ allograft (including corneal transplant).\n\n          -  Any malabsorption condition.\n\n          -  Women who are pregnant or breast-feeding.\n\n          -  Any condition which, in the investigator's opinion, makes the subject unsuitable for\n             trial participation.\n\n          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days\n             before start of study medication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02023333", 
            "org_study_id": "13-211"
        }, 
        "intervention": {
            "arm_group_label": "Regorafenib", 
            "description": "All patients that meet the eligibility criteria who have signed informed consent and have enrolled on the trial will be treated with 160mg (flat dose) of regorafenib, daily 3 weeks on 1 week off. The following assessments should be performed on the first day of each cycle (every 4 weeks) prior to receiving study treatment (+/- 7 days)", 
            "intervention_name": "Regorafenib", 
            "intervention_type": "Device", 
            "other_name": "BAY 73-45060"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Regorafenib", 
            "Performance Status", 
            "13-211"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Andrea Cercek, MD", 
                    "phone": "646-888-4189"
                }, 
                "facility": {
                    "address": {
                        "city": "Basking Ridge", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center at Basking Ridge"
                }, 
                "investigator": {
                    "last_name": "Andrea Cercek, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrea Cercek, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Commack", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11725"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center at Commack"
                }, 
                "investigator": {
                    "last_name": "Andera Cercek, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrea Cercek, MD", 
                    "phone": "646-888-4189"
                }, 
                "contact_backup": {
                    "last_name": "Leonard Saltz, MD", 
                    "phone": "646-888-4181"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Andrea Cercek, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrea Cercek, MD", 
                    "phone": "646-888-4189"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockville Centre", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11570"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center at Mercy Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrea Cercek, MD", 
                    "phone": "646-888-4189"
                }, 
                "facility": {
                    "address": {
                        "city": "Sleepy Hollow", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10591"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center Sleepy Hollow"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma", 
        "overall_contact": {
            "last_name": "Andrea Cercek, MD", 
            "phone": "646-888-4189"
        }, 
        "overall_contact_backup": {
            "last_name": "Leonard Saltz, MD", 
            "phone": "646-888-4181"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Andrea Cercek, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Response and progression will be evaluated in this study using the international criteria proposed by the RECIST 1.1 Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria.", 
            "measure": "progression free survival", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02023333"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall survival is defined as the time from treatment start to death or last follow up. Survival will be estimated using the Kaplan-Meier method.", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Disease control rate (defined with RECIST 1.1 criteria at 16 weeks (2nd scan) as CR, PR or SD), will be estimated using proportions and exact binomial 95% confidence intervals provided.", 
                "measure": "disease control rate", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "description": "Duration of stable disease will be defined as the time from stable disease to the time of documented progression.", 
                "measure": "duration of stable disease", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "will be evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0. The assessments will be based on recorded adverse events, physical examinations, and clinical laboratory assessments. Toxicity will be summarized using descriptive statistics.", 
                "measure": "toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}